e-learning
resources
Munich 2014
Wednesday, 10.09.2014
Novel targets and drugs for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ADEPT-derived, U-BIOPRED validated asthma clinical clusters with Th2 and non-Th2 phenotypes
M. Loza, P. Silkoff, V. Susilic, A. Rowe, I. Adcock, C. Auffray, K. F. Chung, R. Djukanovic, P. Sterk, F. Baribaud (Spring House, United States Of America; London, Southampton, United Kingdom; Lyon, France; Amsterdam, Netherlands)
Source:
International Congress 2014 – Novel targets and drugs for asthma and COPD
Session:
Novel targets and drugs for asthma and COPD
Session type:
Oral Presentation
Number:
4859
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Loza, P. Silkoff, V. Susilic, A. Rowe, I. Adcock, C. Auffray, K. F. Chung, R. Djukanovic, P. Sterk, F. Baribaud (Spring House, United States Of America; London, Southampton, United Kingdom; Lyon, France; Amsterdam, Netherlands). ADEPT-derived, U-BIOPRED validated asthma clinical clusters with Th2 and non-Th2 phenotypes. Eur Respir J 2014; 44: Suppl. 58, 4859
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Th2 subsetting of U-BIOPRED asthma subjects based on airway transciptomic profiles
Source: International Congress 2015 – Advances in the future treatment of severe asthma
Year: 2015
Mutually exclusive Th2 and Th17 bronchial gene expression signatures are associated with eosinophilia in asthma
Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Year: 2014
Gene set variation analysis of mRNA expression in bronchial biopsies from the U-BIOPRED asthma study
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
The first U-BIOPRED sputum handprint of severe asthma
Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey
Year: 2015
TSLP as biomarker in asthma patients
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
The first U-BIOPRED blood handprint of severe asthma
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Peripheral pathological ILC2: An inflammatory indicator for the assessment of asthma control in clinics
Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding
Year: 2016
Levels of cytokines, sCD31 and expression of CD38 in patients with bronchial asthma of various severity out of a disease exacerbation
Source: International Congress 2014 – Biomarkers of asthma and clinical immunology
Year: 2014
Autoreactivity in patients with combined COPD and asthma phenotype
Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma
Year: 2014
Characterisation of a steroid-insensitive severe asthma model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Epidemiological, clinical and morphological features of allergic rhinitis and bronchial asthma in patients of different ages
Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Year: 2014
Discrimination of bronchial inflammatory phenotype of asthmatic patients by using the electronic nose
Source: Annual Congress 2013 –Origins and diagnosis of asthma
Year: 2013
Expression of genes associated with neurogenic inflammation in pediatric asthma
Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules
Year: 2013
Characteristics of the adult corticosteroid-dependent severe asthma in UBIOPRED consortium
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
TLR-3 triggered exacerbation of experimental asthma depends on IL-17 producing NK cells
Source: International Congress 2014 – TH17 and other acute asthmatic responses
Year: 2014
Characteristics of IL-25 and allergen-induced airways fibrosis in a murine model of asthma
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
Pharmacogenetics in severity of bronchial hyperresponsiveness in asthma
Source: Annual Congress 2013 –Genetic factors in airway development and disease
Year: 2013
Investigating the role of BAFF in murine models of allergic asthma
Source: International Congress 2014 – Paediatric asthma: markers and molecules
Year: 2014
Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept